Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

BACKGROUND: Therapies for chronic hepatitis delta virus (HDV) infection are unsatisfactory. Prenylation is essential for HDV and inhibition abrogates HDV production in experimental models. In a proof-of-concept study, we aimed to assess the effect on HDV RNA levels, safety, and tolerability of the p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Infect Dis
Main Authors: Koh, Christopher, Canini, Laetitia, Dahari, Harel, Zhao, Xiongce, Uprichard, Susan L, Haynes-Williams, Vanessa, Winters, Mark A, Subramanya, Gitanjali, Cooper, Stewart L, Pinto, Peter, Wolff, Erin F, Bishop, Rachel, Han, Ma Ai Thanda, Cotler, Scott J, Kleiner, David E, Keskin, Onur, Idilman, Ramazan, Yurdaydin, Cihan, Glenn, Jeffrey S, Heller, Theo
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4700535/
https://ncbi.nlm.nih.gov/pubmed/26189433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(15)00074-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados